NCT00591188View on ClinicalTrials.gov

Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

May 31, 2008

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

capecitabine, interferon-alpha

Patients who meet inclusion/exclusion criteria will receive combination of study drugs.

Trial Locations (1)

115478

N.N. Blokhin Russian Cancer Research Center, Moscow

All Listed Sponsors
lead

Kidney Cancer Research Bureau

OTHER

NCT00591188 - Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens | Biotech Hunter | Biotech Hunter